+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cardiac Point of Care Testing Market by Product, Biomarker Type, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 185 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5924931
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cardiac Point of Care Testing Market grew from USD 8.31 billion in 2023 to USD 9.38 billion in 2024. It is expected to continue growing at a CAGR of 13.14%, reaching USD 19.74 billion by 2030.

Cardiac Point of Care Testing (POCT) refers to the rapid diagnostic tests conducted near a patient's location for quick assessment of cardiovascular health, reducing the time between diagnosis and treatment. The necessity of cardiac POCT lies in its potential to deliver immediate results, fundamental in conditions like heart attacks, where time is critical. These tests are commonly applied in emergency rooms, clinics, and even home settings, aiming to measure cardiac biomarkers that indicate heart stress or injury, such as troponin. The end-use scope spans hospitals, diagnostic centers, ambulatory care, and home healthcare, suggesting a widespread applicability across various healthcare settings. Market growth is largely influenced by increasing incidences of cardiovascular diseases, advancements in technology fostering quicker and more accurate tests, and a rising demand for decentralized healthcare solutions. Emerging trends like miniaturization and the integration of AI for predictive analyses present significant opportunities; companies should focus on partnerships with tech firms to innovate their offerings and improve diagnostic accuracy. Limitations include variability in test results impacting clinical decisions and high costs associated with advanced technologies, which may hinder adoption, especially in developing regions. Moreover, regulatory challenges and the need for substantial infrastructure investment can impede market expansion. Nevertheless, areas ripe for innovation encompass the development of portable, user-friendly devices that allow self-testing, thereby enhancing patient compliance and monitoring. By capitalizing on AI and IoMT (Internet of Medical Things), companies can offer comprehensive solutions that merge diagnostic capabilities with data analytics for predictive insights. The market is rapidly evolving with consumer expectations leaning towards more personalized and decentralized healthcare. As such, firms must focus on sustainability by investing in adaptable technological solutions that offer improved integration across healthcare platforms, addressing both immediate diagnostic needs and long-term health management strategies.

Understanding Market Dynamics in the Cardiac Point of Care Testing Market

The Cardiac Point of Care Testing Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing incidences of cardiovascular disorders among the population
    • Favorable government initiatives for the introduction of POC testing
    • Improving healthcare expenditure across economies worldwide
  • Market Restraints
    • Fluctuating cost of materials and components used in cardiac POC testing
  • Market Opportunities
    • Improvements and continuous advancements in cardiac POC testing
    • Advances in the development of new biomarkers to improve testing capabilities
  • Market Challenges
    • Operational and technical complexities in cardiac POC testing

Exploring Porter’s Five Forces for the Cardiac Point of Care Testing Market

Porter’s Five Forces framework further strengthens the insights of the Cardiac Point of Care Testing Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Cardiac Point of Care Testing Market

External macro-environmental factors deeply influence the performance of the Cardiac Point of Care Testing Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Cardiac Point of Care Testing Market

The Cardiac Point of Care Testing Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Cardiac Point of Care Testing Market

The Cardiac Point of Care Testing Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Cardiac Point of Care Testing Market

The Cardiac Point of Care Testing Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Point of Care Testing Market, highlighting leading vendors and their innovative profiles. These include Abaxis, Inc. by Zoetis Inc, Abbott Laboratories, ACON Laboratories, Inc., Beckman Coulter, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Cardiac Insight Inc., CardioGenics Holdings Inc., Chembio Diagnostic Systems, Inc. by Biosynex, EKF Diagnostics, F. Hoffmann-La Roche Ltd., Fujirebio, Horiba, Ltd., I-Sens Inc., LifeSign LLC, Nexus Dx, Inc. by Sinocare, Nova Biomedical, PTS Diagnostics by Danaher Corporation, Quidel Corporation, Radiometer Medical ApS, Randox Laboratories Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trividia Health, Inc..

Market Segmentation & Coverage

This research report categorizes the Cardiac Point of Care Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Product
    • Analyzers
    • Kits & Assays
    • Software & Services
  • Biomarker Type
    • Cardiac Troponins
    • CK-MB Fraction
    • D-Dimer
    • Heart-Type Fatty Acid-Binding Protein (H-FABP)
    • Homocysteine
    • hs C-reactive Protein (CRP)
    • Ischemia-Modified Albumin (IMA)
    • Myoglobin
    • Natriuretic Peptides (NPs)
      • Atrial Natriuretic Peptide (ANP)
      • B-type Natriuretic Peptide (BNP)
      • N-terminal proBNP (NT-proBNP)
    • sCD40L
  • End-User
    • Diagnostic Laboratories
    • Hospitals & Clinics
    • Research & Academic Institutes
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidences of cardiovascular disorders among the population
5.1.1.2. Favorable government initiatives for the introduction of POC testing
5.1.1.3. Improving healthcare expenditure across economies worldwide
5.1.2. Restraints
5.1.2.1. Fluctuating cost of materials and components used in cardiac POC testing
5.1.3. Opportunities
5.1.3.1. Improvements and continuous advancements in cardiac POC testing
5.1.3.2. Advances in the development of new biomarkers to improve testing capabilities
5.1.4. Challenges
5.1.4.1. Operational and technical complexities in cardiac POC testing
5.2. Market Segmentation Analysis
5.2.1. Product: Increasing demand for multiplex assays across clinics
5.2.2. Biomarker Type: Increasing demand for heart-type fatty acid-binding protein (H-FABP) and ischemia-modified albumin (IMA) for early cardiac detection
5.2.3. End-user: Rising usage of cardiac POC testing in diagnostic laboratories for complex systems with high sample capacities
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Cardiac Point of Care Testing Market, by Product
6.1. Introduction
6.2. Analyzers
6.3. Kits & Assays
6.4. Software & Services
7. Cardiac Point of Care Testing Market, by Biomarker Type
7.1. Introduction
7.2. Cardiac Troponins
7.3. CK-MB Fraction
7.4. D-Dimer
7.5. Heart-Type Fatty Acid-Binding Protein (H-FABP)
7.6. Homocysteine
7.7. hs C-reactive Protein (CRP)
7.8. Ischemia-Modified Albumin (IMA)
7.9. Myoglobin
7.10. Natriuretic Peptides (NPs)
7.10.1. Atrial Natriuretic Peptide (ANP)
7.10.2. B-type Natriuretic Peptide (BNP)
7.10.3. N-terminal proBNP (NT-proBNP)
7.11. sCD40L
8. Cardiac Point of Care Testing Market, by End-User
8.1. Introduction
8.2. Diagnostic Laboratories
8.3. Hospitals & Clinics
8.4. Research & Academic Institutes
9. Americas Cardiac Point of Care Testing Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cardiac Point of Care Testing Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cardiac Point of Care Testing Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. Hipro Point-of-Care Diagnostics Launched in India
12.3.2. Jana Care to Enter Collaboration with Roche to Develop and Distribute Blood Testing Platform to Improve Remote Care for Patients With Chronic Kidney and Heart Disease
12.3.3. Cipla expands diagnostics portfolio, launches point-of-care testing device
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. CARDIAC POINT OF CARE TESTING MARKET RESEARCH PROCESS
FIGURE 2. CARDIAC POINT OF CARE TESTING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. CARDIAC POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. CARDIAC POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CARDIAC POINT OF CARE TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CARDIAC POINT OF CARE TESTING MARKET DYNAMICS
TABLE 7. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CARDIAC TROPONINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY CK-MB FRACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY D-DIMER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HEART-TYPE FATTY ACID-BINDING PROTEIN (H-FABP), BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOMOCYSTEINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HS C-REACTIVE PROTEIN (CRP), BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ISCHEMIA-MODIFIED ALBUMIN (IMA), BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY ATRIAL NATRIURETIC PEPTIDE (ANP), BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE (BNP), BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY N-TERMINAL PROBNP (NT-PROBNP), BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY SCD40L, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 33. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 42. BRAZIL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 44. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 45. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 46. CANADA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 48. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 49. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 50. MEXICO CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 62. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 65. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 66. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 67. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 68. CHINA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 70. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 71. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 72. INDIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 74. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 75. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 76. INDONESIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 78. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 79. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 80. JAPAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 82. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 83. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 84. MALAYSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 86. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 87. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 88. PHILIPPINES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 90. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 91. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 92. SINGAPORE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 94. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 95. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 96. SOUTH KOREA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 98. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 99. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 100. TAIWAN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 102. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 103. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 104. THAILAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 106. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 107. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 108. VIETNAM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 114. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 115. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 116. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 117. DENMARK CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 119. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 120. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 121. EGYPT CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 123. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 124. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 125. FINLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 127. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 128. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 129. FRANCE CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 131. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 132. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 133. GERMANY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 135. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 136. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 137. ISRAEL CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 139. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 140. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 141. ITALY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 143. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 144. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 145. NETHERLANDS CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 147. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 148. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 149. NIGERIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 151. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 152. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 153. NORWAY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 155. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 156. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 157. POLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 159. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 160. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 161. QATAR CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 165. RUSSIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 175. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 176. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 177. SPAIN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 181. SWEDEN CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 183. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 184. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 185. SWITZERLAND CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 187. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 188. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 189. TURKEY CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 191. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY NATRIURETIC PEPTIDES (NPS), 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM CARDIAC POINT OF CARE TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 198. CARDIAC POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2023
TABLE 199. CARDIAC POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Cardiac Point of Care Testing Market, which are profiled in this report, include:
  • Abaxis, Inc. by Zoetis Inc
  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • Beckman Coulter
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Cardiac Insight Inc.
  • CardioGenics Holdings Inc.
  • Chembio Diagnostic Systems, Inc. by Biosynex
  • EKF Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • Fujirebio
  • Horiba, Ltd.
  • I-Sens Inc.
  • LifeSign LLC
  • Nexus Dx, Inc. by Sinocare
  • Nova Biomedical
  • PTS Diagnostics by Danaher Corporation
  • Quidel Corporation
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trividia Health, Inc.

Methodology

Loading
LOADING...

Table Information